At AMWC 2024, Galderma presents new data on Restylane® SHAYPE™, RelabotulinumtoxinA, and Sculptra® for the body.
At AMWC 2024, Galderma will present new data from its leading injectable aesthetic portfolio, showcasing its diverse range of treatments through 16 research posters and two sponsored symposia. The company will present clinical data on Restylane® SHAYPE™, an innovative hyaluronic acid technology, and RelabotulinumtoxinA, a neuromodulator. The event will also highlight insights from the 'NEXT by Galderma' future aesthetic trends report and the use of Sculptra® for the body.
March 19, 2024
5 Articles